The immunosuppressive agent 15-deoxyspergualin, which inhibits HSC70 activity by binding to the C-terminus of HSC70 but not to that of HSP70 or HSP90, was approved for the treatment of glomerulonephritis associated with active systemic lupus erythematosus35. Here, HSPA8 is linked to glomerulonephritis.